Tufton Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.71M Sell
64,310
-60
-0.1% -$3.44K 0.62% 46
2026
Q1
$3.9M Sell
64,370
-458
-0.7% -$26.7K 0.71% 49
2025
Q4
$3.5M Sell
64,828
-6,897
-10% -$332K 0.61% 51
2025
Q3
$3.23M Sell
71,725
-1,781
-2% -$83.2K 0.58% 52
2025
Q2
$3.4M Sell
73,506
-4,575
-6% -$225K 0.65% 52
2025
Q1
$4.76M Sell
78,081
-1,314
-2% -$76.6K 0.92% 42
2024
Q4
$4.49M Sell
79,395
-3,304
-4% -$185K 0.85% 43
2024
Q3
$4.28M Sell
82,699
-4,632
-5% -$217K 0.8% 43
2024
Q2
$3.63M Sell
87,331
-4,709
-5% -$211K 0.71% 47
2024
Q1
$4.99M Sell
92,040
-42,508
-32% -$2.17M 0.98% 38
2023
Q4
$6.9M Sell
134,548
-5,788
-4% -$304K 1.45% 31
2023
Q3
$8.15M Sell
140,336
-2,518
-2% -$154K 1.82% 18
2023
Q2
$9.14M Sell
142,854
-2,548
-2% -$171K 1.97% 15
2023
Q1
$10.1M Sell
145,402
-907
-0.6% -$64K 2.18% 14
2022
Q4
$10.5M Sell
146,309
-2,808
-2% -$212K 2.32% 14
2022
Q3
$10.6M Sell
149,117
-32,760
-18% -$2.38M 2.56% 7
2022
Q2
$14M Sell
181,877
-584
-0.3% -$44.5K 2.62% 9
2022
Q1
$13.3M Sell
182,461
-2,703
-1% -$181K 2.15% 13
2021
Q4
$11.5M Buy
185,164
+935
+0.5% +$54.8K 1.77% 19
2021
Q3
$10.9M Sell
184,229
-108
-0.1% -$7.11K 1.85% 17
2021
Q2
$12.3M Sell
184,337
-6,084
-3% -$397K 2.02% 15
2021
Q1
$12M Buy
190,421
+1,569
+0.8% +$97.6K 2.05% 18
2020
Q4
$11.7M Buy
188,852
+5,343
+3% +$329K 2.16% 16
2020
Q3
$11.1M Sell
183,509
-1,400
-0.8% -$84.3K 2.29% 14
2020
Q2
$10.9M Sell
184,909
-30
-0% -$1.79K 2.39% 14
2020
Q1
$10.3M Sell
184,939
-533
-0.3% -$32.6K 2.64% 10
2019
Q4
$11.9M Buy
185,472
+14,554
+9% +$834K 2.34% 12
2019
Q3
$8.67M Sell
170,918
-1,650
-1% -$77.5K 1.83% 22
2019
Q2
$7.83M Buy
172,568
+5,447
+3% +$254K 1.65% 25
2019
Q1
$7.97M Buy
167,121
+4,317
+3% +$215K 1.7% 24
2018
Q4
$8.46M Sell
162,804
-2,519
-2% -$135K 2.08% 16
2018
Q3
$10.3M Sell
165,323
-1,890
-1% -$112K 2.18% 14
2018
Q2
$9.25M Sell
167,213
-1,209
-0.7% -$65.3K 1.98% 15
2018
Q1
$10.7M Sell
168,422
-3,405
-2% -$219K 2.1% 11
2017
Q4
$10.5M Sell
171,827
-282
-0.2% -$17.6K 2.03% 11
2017
Q3
$11M Buy
172,109
+2,425
+1% +$142K 2.19% 11
2017
Q2
$9.46M Buy
169,684
+32,310
+24% +$1.76M 1.92% 13
2017
Q1
$7.47M Buy
137,374
+3,007
+2% +$165K 1.47% 25
2016
Q4
$7.85M Buy
134,367
+8,476
+7% +$463K 1.59% 23
2016
Q3
$6.79M Buy
125,891
+29,606
+31% +$1.9M 1.37% 31
2016
Q2
$7.08M Sell
96,285
-3,109
-3% -$220K 1.43% 27
2016
Q1
$6.35M Sell
99,394
-831
-0.8% -$52.4K 1.58% 29
2015
Q4
$6.89M Sell
100,225
-1,707
-2% -$113K 1.7% 22
2015
Q3
$6.03M Sell
101,932
-3,598
-3% -$228K 1.33% 27
2015
Q2
$7.02M Sell
105,530
-6,676
-6% -$440K 1.42% 23
2015
Q1
$7.24M Sell
112,206
-450
-0.4% -$28.2K 1.33% 26
2014
Q4
$6.65M Sell
112,656
-2,173
-2% -$123K 1.22% 32
2014
Q3
$5.88M Sell
114,829
-1,705
-1% -$85.2K 1.1% 36
2014
Q2
$5.65M Sell
116,534
-17,500
-13% -$862K 1.15% 35
2014
Q1
$6.96M Sell
134,034
-14,775
-10% -$786K 1.46% 24
2013
Q4
$7.91M Sell
148,809
-1,669
-1% -$85K 1.69% 15
2013
Q3
$6.96M Sell
150,478
-1,895
-1% -$83.2K 1.64% 15
2013
Q2
$6.81M Buy
+152,373
New +$6.62M 1.64% 17

Other funds holding BMY

Tufton Capital Management's BMY Position: Q2 2026 in Review

Tufton Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.09% in Q2 2026, selling an estimated $3.44K and leaving 64,310 shares worth $3.71M. The position accounts for 0.62% of the portfolio, ranked #46.

Tufton Capital Management first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $14M in Q2 2022. 832 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Tufton Capital Management held 64,310 shares of Bristol-Myers Squibb worth $3.71M as of Q2 2026.
  • Tufton Capital Management sold 60 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.44K.
  • Bristol-Myers Squibb made up 0.62% of Tufton Capital Management's portfolio in Q2 2026, its #46 holding.
  • Tufton Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Tufton Capital Management's Bristol-Myers Squibb position peaked at $14M in Q2 2022.
  • 832 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Tufton Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.